Hookipa Pharma Ownership
| HOOK Stock | USD 1.60 0.16 9.09% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 12.5 M | Current Value 12.5 M | Avarage Shares Outstanding 31.6 M | Quarterly Volatility 21.1 M |
Hookipa |
Hookipa Stock Ownership Analysis
About 59.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hookipa Pharma recorded a loss per share of 3.67. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 10th of July 2024. HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company was incorporated in 2011 and is headquartered in New York, New York. Hookipa Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people. To learn more about Hookipa Pharma call Joern Aldag at 431 890 6360 or check out https://www.hookipapharma.com.Besides selling stocks to institutional investors, Hookipa Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Hookipa Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Hookipa Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Hookipa Pharma Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Hookipa Pharma are currently held by insiders. Unlike Hookipa Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Hookipa Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Hookipa Pharma's insider trades
Hookipa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hookipa Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hookipa Pharma backward and forwards among themselves. Hookipa Pharma's institutional investor refers to the entity that pools money to purchase Hookipa Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 25.3 K | Engineers Gate Manager Lp | 2024-12-31 | 23.7 K | Royal Bank Of Canada | 2024-12-31 | 19.4 K | State Street Corp | 2024-12-31 | 17 K | Northern Trust Corp | 2024-12-31 | 15.7 K | Millennium Management Llc | 2024-12-31 | 15.3 K | Blackrock Inc | 2024-12-31 | 12.2 K | Boothbay Fund Management, Llc | 2024-09-30 | 11.8 K | Prudential Financial Inc | 2024-12-31 | 11.4 K | Baker Bros Advisors Lp | 2024-12-31 | 812.8 K | Siren, L.l.c. | 2024-12-31 | 566.6 K |
Hookipa Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hookipa Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hookipa Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hookipa Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hookipa Pharma Outstanding Bonds
Hookipa Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hookipa Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hookipa bonds can be classified according to their maturity, which is the date when Hookipa Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.67) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.